ArticlePloS one2022

Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data.

Eiichi Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.